Doramapimod (BIRB 796)

For research use only.

Catalog No.S1574

63 publications

Doramapimod (BIRB 796) Chemical Structure

Molecular Weight(MW): 527.66

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 288 In stock
EUR 144 In stock
EUR 265 In stock
EUR 461 In stock
EUR 1444 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Doramapimod (BIRB 796) has been cited by 63 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.
Features The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
p38α [1]
(Cell-free assay)
p38α [7]
0.1 nM(Kd) 38 nM
In vitro

BIRB 796 shows no significant inhibition to ERK-1, SYK, IKK2β, ZAP-70, EGF receptor kinase, HER2, protein kinase A (PKA), PKC, PKC-α, PKC-β (I and II) and PKC-γ. BIRB 796 greatly improves binding affinity by forming a hydrogen bond between the morpholine oxygen and the ATP-binding domain of p38α. BIRB 796 represents one of the most potent and slowest dissociating inhibitors against human p38 MAP kinase now known. [1] BIRB 796 potently inhibits c-Raf-1 and Jnk2α2 with IC50 of 1.4 and 0.1 nM, respectively. [2] BIRB796 also inhibits the activity and the activation of SAPK3/p38γ at a higher concentration than it does in p38α. BIRB796 blocks the stress-induced phosphorylation of the scaffold protein SAP97, which is a physiological substrate of SAPK3/p38γ. BIRB796 blocks JNK1/2 activation and activity in HEK293 cells, while not inhibits the activation and activity of ERK1/ERK2 in Hela cells. Moreover, the binding of BIRB796 to the p38 MAPKs or JNK1/2 is impairing their phosphorylation by the upstream kinase MKK6 or MKK4 rather than enhancing their dephosphorylation. [3] BIRB 796 blocks baseline and bortezomib-triggered upregulation of p38 MAPK and Hsp27 phosphorylation, thereby enhancing cytotoxicity and caspase activation. BIRB 796 downregulates IL-6 and VEGF secretion in BMSCs triggered by TNF-α and TGF-β1. [4] BIRB-796 has a pyrazole scaffold that places a lipophilic t-butyl group into the lower selectivity site and a tolyl ring into the upper selectivity site. BIRB-796 also inhibits B-Raf and Abl with IC50 of 83 nM and 14.6 μM, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NXTxc|VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH1OXlqUUN3ME2wMlM1PzZ|IN88US=> NWf2[Zh6W0GQR2LFVi=>
DU-145 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTNwOUO4NVEh|ryP MkjtV2FPT1KHUh?=
IST-MES1 M2noXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTOV|Y5UUN3ME23Mlk2PjN5IN88US=> M3jRRXNCVkeURWK=
KP-N-YN MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRThwMkCxPUDPxE1? Mo\1V2FPT1KHUh?=
T-24 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rRfGlEPTB;OD60NFY4OyEQvF2= NX\KTphFW0GQR2LFVi=>
MPP-89 NGDZTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PJcmlEPTB;OD60OlI2OSEQvF2= M3\ifHNCVkeURWK=
NCI-SNU-1 NHfHfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTlwME[3N|kh|ryP NVi1NnREW0GQR2LFVi=>
NBsusSR MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzjTWM2OD1zMD64NlM2KM7:TR?= NIDzc4VUSU6JUlXS
BEN NHnObFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\pRYdKSzVyPUGzMlEzPjRizszN MUjTRW5IWkWU
HMV-II M4PVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj2TWM2OD1zND6yN|A6KM7:TR?= NYTWW3NUW0GQR2LFVi=>
NCI-H1581 MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPZTWM2OD1zNz6wOFQ4KM7:TR?= NXvP[XlwW0GQR2LFVi=>
ES8 MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPlWJhKSzVyPUG3MlE3PyEQvF2= NU\oNopvW0GQR2LFVi=>
LC-2-ad MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3IXZJKSzVyPUG3MlQ{PjZizszN M1zhWHNCVkeURWK=
AN3-CA M4jq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHOTWM2OD1zOD6xJO69VQ>? M{TMfnNCVkeURWK=
DB NHjPSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDyTWtKSzVyPUG4Mlc6OjNizszN MlTWV2FPT1KHUh?=
SK-MEL-1 M4\ZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvPXWFCUUN3ME2yNE4{Pjh|IN88US=> NF\GNldUSU6JUlXS
CAPAN-1 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTHS4pKSzVyPUKyMlE5QDRizszN NXOyeYpVW0GQR2LFVi=>
NCI-H2228 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfIO4VqUUN3ME2yN{43PjZ6IN88US=> MkPaV2FPT1KHUh?=
KYSE-270 M33TT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jF[2lEPTB;MkSuOVU4OyEQvF2= NVXsd25RW0GQR2LFVi=>
HCC1806 NILO[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\tbZlKSzVyPUK0Mlc4QTlizszN NWCyUGpiW0GQR2LFVi=>
HuO-3N1 M3jQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJ3LkixPFUh|ryP NHrMNnJUSU6JUlXS
HOS M{D4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJ3LkmyPVIh|ryP NGDOVpFUSU6JUlXS
COLO-741 NViydmtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXpTWM2OD1{Nj6zN|I6KM7:TR?= MlPjV2FPT1KHUh?=
HCC1937 M2rO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTtTWM2OD1{Nz6yNlM5KM7:TR?= Mn;sV2FPT1KHUh?=
NCI-H2126 NGTNemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fXNGlEPTB;MkeuN|k4PSEQvF2= M{[1bnNCVkeURWK=
NCI-H1703 M{nTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rLNGlEPTB;MkiuNFQyOyEQvF2= M1H2dXNCVkeURWK=
U-2-OS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnqeolKSzVyPUK4MlU2OTVizszN NHLoXmtUSU6JUlXS
MHH-ES-1 NHOzc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTNzLkm0NUDPxE1? NH3hRWJUSU6JUlXS
HCC1419 NXT6WYV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTPb4R{UUN3ME2zNk4yOTF7IN88US=> Mlm5V2FPT1KHUh?=
HOP-62 M4nWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnpVo5sUUN3ME2zNk4zPzBzIN88US=> M1HUTnNCVkeURWK=
AM-38 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPGbmprUUN3ME2zNk46QTNzIN88US=> NH:4c25USU6JUlXS
NCI-H2009 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17QbWlEPTB;M{OuOFAxPyEQvF2= MknNV2FPT1KHUh?=
EM-2 NVjqempDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLMTWM2OD1|Mz61OVEyKM7:TR?= MoXJV2FPT1KHUh?=
SW1116 NHnER3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnzTWM2OD1|ND60PFM5KM7:TR?= MXnTRW5IWkWU
SK-N-AS MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnZTWM2OD1|NT6wO|E1KM7:TR?= NGDscYxUSU6JUlXS
ChaGo-K-1 M{LKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy2cWdCUUN3ME2zOU43ODN{IN88US=> M1vhXXNCVkeURWK=
RT-112 NF7hToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTN3Lkm4O|kh|ryP M4n0OnNCVkeURWK=
SK-NEP-1 M3vKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[zOHZKSzVyPUO2MlYyODZizszN MkDvV2FPT1KHUh?=
CTB-1 MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT6TI5QUUN3ME2zPE41PTF{IN88US=> MljBV2FPT1KHUh?=
MOLT-4 M4T4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPzTWM2OD1|OD64N|kyKM7:TR?= M4LF[XNCVkeURWK=
SW756 NUPDfWxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn3c3BKSzVyPUSwMlk{QDVizszN M3rNbHNCVkeURWK=
CAL-72 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLMTWM2OD12Mj6wN{DPxE1? NF;Eb4pUSU6JUlXS
KP-4 NEe4RpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnZZVNnUUN3ME20Ok44OzZzIN88US=> MkD5V2FPT1KHUh?=
NEC8 NWe2emlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrTTWM2OD12Nz6xOlYyKM7:TR?= NFvBflZUSU6JUlXS
G-402 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv2NVhKSzVyPUS4MlcxOTJizszN MWnTRW5IWkWU

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
p-p38 / p38 ; 

PubMed: 23349819     

The inhibitory effect of phosphorylated p38 in KB, KBV200 (B) and in MCF-7, MCF-7/ADR (C) treated with BIRB796 at various concentrations after 24 h. 

mTOR / p-S6K / S6K / p-MK2 / MK2 / p-Hsp27 / Hsp27 ; 

PubMed: 26844273     

CRC cells were treated with 4 μM LY2228820, 10 μM BIRB796 or 10 μM SB202190 for 2 h and p38 and mTORC1 signaling was analyzed by immunoblot.

p-p38 / γ-H2AX ; 

PubMed: 27082306     

The expression of p-P38 was tested via protein gel blot after the cells were treated with BIRB796.

23349819 26844273 27082306
In vivo BIRB 796 (30 mg/kg) inhibits 84% of TNF-α in LPS-stimulated mice and demonstrates efficacy in a mouse model of established collagen-induced arthritis. [1] BIRB 796 has good pharmacokinetic performance even after oral administration in mice. [2]


Animal Research:


- Collapse
  • Animal Models: Collagen-induced arthritis in female Balb/c mice
  • Dosages: 1 mg/kg (intravenous) or 10 mg/kg (oral)
  • Administration: Intravenous injection or by oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (189.51 mM)
Water Insoluble
Ethanol '100 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG300+5%Tween80 +50%H2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 527.66


CAS No. 285983-48-4
Storage powder
in solvent
Synonyms N/A
Smiles CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy Doramapimod (BIRB 796) | Doramapimod (BIRB 796) supplier | purchase Doramapimod (BIRB 796) | Doramapimod (BIRB 796) cost | Doramapimod (BIRB 796) manufacturer | order Doramapimod (BIRB 796) | Doramapimod (BIRB 796) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID